



Ref.-AL/CS/STX/2018/16

August 09, 2018.

The Manager (Department of Corporate Services)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, 25th Floor, Dalal Street, Fort
Mumbai- 400001

Scrip Code: 526707

The Manager (Listing Department)
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Bandra Kurla Complex
Bandra (East), Mumbai- 400051

Scrip Code: ALCHEM

Sub: Outcome of Board Meeting

Dear Sir/Madam,

We wish to inform you that the Board of Directors in its meeting held on 09.08.2018 has considered and approved the following:

1. Unaudited Financial Results (Provisional) of the Company for the quarter/three months ended on 30th June, 2018. A copy of the results is attached as Annexure -1.
2. Limited review Report on the Unaudited Financial Results for the quarter/three months ended on 30th June, 2018 obtained from Statutory Auditors has also been taken on record and a copy of the same is attached as Annexure -2.

An extracts of the aforementioned financial results would be published in the newspaper in accordance with the Listing Regulations.

3. Notice of 29th Annual General Meeting of the Company to be held on Tuesday, 25th September, 2018.
4. The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday, 18th September, 2018 to Tuesday, 25th September, 2018 (both days inclusive).
5. Considered Draft Annual Report for the Financial Year 2017-18.
6. Any other matter with the permission of chair (if any).

You are requested to take the above information on your record & acknowledge the same.

Thanking you
Yours Sincerely
For **ALCHEMIST LIMITED**


Hemant Kumar Mangal
(Company Secretary)



ALCHEMIST LTD.

CIN : L72200DL1988PLC192643

Annexure-1

ALCHEMIST LIMITED

REGD.OFFICE : 23 NEHRU PLACE, NEW DELHI-110 019


CIN NO.:I72200DL1988PLC192643. Tel No.: (91-11) 40600800. Fax: (91-11) 40600888. E-mail: info@alchemist.co.in. Website: www.alchemist.co.in

PART I: STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

S.No	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		30.06.2018 (Unaudited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)*	31.03.18 (Audited)
		(₹ in Lacs except EPS data)			
1	Net Sales (Net of Excise Duty) / Incomes from Operations	865.80	595.35	665.29	2660.01
2	Other Income	0.64	29.42	61.71	75.65
3	Total Revenue (1+2)	866.44	624.76	727.01	2735.67
4	Expenditure				
	a) Consumption of Raw Material & Others	272.18	83.67	171.31	509.42
	b) Purchase of stock in trade	310.88	(42.07)	282.19	945.09
	c) (increase)/decrease in stock in trade, finished goods and work in progress	13.08	321.15	24.77	449.64
	d) Employees benefit expenses	204.81	295.81	196.08	955.73
	e) Finance costs	34.27	50.07	39.69	171.53
	f) Depreciation & Amortisation	175.71	196.46	184.97	776.21
	g) Other Expenditure				
	(i) Foreign Exchange (Gain)/Loss	(1851.16)	52.78	(585.46)	(107.73)
	(ii) Other Expenditure other than (i) above	152.63	198.35	252.87	751.91
	Total Expenses	(687.60)	1156.23	566.42	4451.80
5	Profit before Exceptional & Extraordinary Items (3-4)	1554.04	(531.47)	160.59	(1716.13)
6	Exceptional Items	-	-	-	(71.14)
7	Profit Before Tax (5-6-7)	1554.04	(531.47)	160.59	(1644.99)
8	Tax Expenses				
	a) Current Tax				
	b) Deferred Tax	(18.12)	36.09	37.40	42.07
9	Profit(+)/ Loss(-) for the period (8-9)	1572.16	(567.56)	123.19	(1687.06)

4.4

10	Other Comprehensive Income							
	Items that will not be reclassified to profit or loss							
	Re-measurement of the net defined benefit plans	(20.52)	27.81	16.31	49.14			
	Tax on above	5.34	(8.59)	(4.24)	(12.78)			
11	Total Other comprehensive Income, net of tax	(15.19)	19.22	12.08	36.37			
12	Total comprehensive Income, for the period	1556.97	(548.34)	135.27	(1650.69)			
13	Paid up equity share capital	1355.98	1355.98	1355.98	1355.98			
	(Face Value of ₹ 10/- each per share)							
14	Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items							
	-Basic	11.59	(4.19)	0.91	(12.44)			
	-Diluted	11.59	(4.19)	0.91	(12.44)			



PART II: SEGMENT INFORMATION FOR THE QUARTER ENDED 30.06.2018

(₹ in Lacs)

S.No.	Particulars	STANDALONE				Year Ended
		Quarter Ended		31.03.2018 (Audited)*	31.03.18 (Audited)	
		30.06.2018 (Unaudited)	30.06.2017 (Unaudited)			
1	Segment Revenue (Net)					
	a) Pharma, Chemical & Minerals	524.60	470.11	400.43	1902.73	
	b) Agri Business	341.21	125.24	264.86	757.28	
	Sub-Total	865.80	595.35	665.29	2660.01	
	Less inter Segment Revenue	-	-	-	-	
	Net Sales/Incomes	865.80	595.35	665.29	2660.01	
2	Segment Results					
	Profit/(Loss) before tax and interest from segments)					
	a) Pharma, Chemical & Minerals	1685.05	(430.39)	109.30	(1459.29)	
	b) Agri Business	(97.37)	(80.42)	29.26	(160.97)	
	Total	1587.68	(510.81)	138.56	(1620.26)	
	Less: Financial Charges	34.27	50.07	39.69	171.53	
	Add: Other Incomes	0.64	29.42	61.71	75.65	
	Less: Exceptional Item	-	-	0.00	(71.14)	
	Total Profit before Tax	1554.04	(531.47)	160.59	(1644.99)	
	Current and Deferred Tax	(18.12)	36.09	37.40	42.07	
	Total Profit after Tax	1572.16	(567.56)	123.19	(1687.06)	
3	Segment Assets					
	a) Pharma, Chemical & Minerals	2282.50	2193.15	1997.22	1997.22	
	b) Agri Business	991.33	912.21	964.98	964.98	
	Total Assets	3273.83	3105.36	2962.20	2962.20	
4	Segment Liabilities					
	a) Pharma, Chemical & Minerals	1723.54	1438.94	1428.94	1428.94	
	b) Agri Business	165.93	85.89	152.62	152.62	
	Total Liabilities	1889.47	1524.83	1581.56	1581.56	
5	Capital Employed					
	(Segment assets-Segment Liabilities)					
	a) Pharma, Chemical & Minerals	558.96	754.21	568.27	568.27	
	b) Agri Business	825.39	826.32	812.37	812.37	
	Total	1384.36	1580.53	1380.64	1380.64	


4


NOTES :

- 1) The above standalone financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 9th August, 2018. The Statutory Auditors have expressed modified opinion on these results.
- *2) The figures for the quarter ended 31st March, 2018 are the balancing figure of the year ended 31st March, 2018 and published financial results of nine months ended 31st December, 2017.
- 3) The figures for the previous period have been regrouped/reclassified, wherever necessary to conform to the current period's presentation.
- 4) The company extends credit from time to time as per market practices. In respect of export receivables amounting to Rs. 48964.14 lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same. The management is confident of recovering all such dues and hence no provision is considered necessary against these receivables.
- 5) The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the company now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The standalone financial statements, as such have been prepared on a going concern basis.
- 6) Foreign exchange translation resulted in gain of Rs. 1851.16 lacs for the three months ended June 30, 2018 reflected under other expenses.

Place: New Delhi
Date: 09/08/18

For Alchemist Limited


Bikram Bhattacharya
(Whole Time Director)



4

ANU AND ASSOCIATES
CHARTERED ACCOUNTANTS

1081, SECTOR 27-B,
CHANDIGARH - 160 019
PH: +91 172 5088800
e-mail: anuandassociates@gmail.com

Independent Auditor's Review Report on Quarterly Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Alchemist Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Alchemist Limited** ("the Company"), having registered office at Alchemist House, 23-Nehru Place, New Delhi, for the quarter ended 30th June, 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Attention is invited to note no. 4 of the accompanying statement which states that "The Company extends credit from time to time as per market practices. In respect of export receivables amounting to Rs. 48964.14 lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same. The management is confident of recovering all such dues and hence no provision is considered necessary against these receivables".

Such export receivables are outstanding for more than three years as at the quarter end date, however, no provision is made against such doubtful trade receivables.

The loss to that extent is under stated, the effect however could not be quantified.

4. Based on our review conducted as above, *subject to the impact of our observation in paragraph 3 above*, nothing else has come to our attention that causes us to believe that the accompanying statement of un-audited standalone financial results prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.




5. Attention is invited to note no. 5 of the accompanying statement which states that "The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the company now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The standalone financial results, as such have been prepared on a going concern basis".


Our review report is not qualified in respect of the matter as stated in the above paragraph.

6. Further, attention is drawn to the fact that the comparative financial information of the Company for the quarter ended 30th June, 2017 prepared in accordance with Indian Accounting Standards (Ind AS) included in this Statement has been reviewed by the predecessor auditor. The report of the predecessor auditor on comparative financial information for the quarter ended 30th June, 2017 dated 10th August, 2017 expressed a qualified opinion.

Our review report is not qualified in respect of the matter as stated in the above paragraph.

for Anu and Associates
Chartered Accountants
Firm Registration No.: 019624N


CA. Parveen Kumar
Partner
Membership No.: 531655



Place of signature: New Delhi
Date: 9th August, 2018